Genmark Diagnostics, Inc. (GNMK): Hany Massarany , President and CEO of Genmark Diagnostics, Inc. sold 1,188 shares on Jun 7, 2016. The Insider selling transaction was reported by the company on Jun 7, 2016 to the Securities and Exchange Commission. The shares were sold at $8.98 per share for a total value of $10,668.24 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 11, 2016, Ingo Chakravarty (SVP, International) sold 582 shares at $5.42 per share price.On May 4, 2016, Jon Faiz Kayyem (SVP, Research & Development) sold 135 shares at $5.79 per share price.Also, On May 4, 2016, Jennifer Anne Williams (SVP, Human Resources) sold 331 shares at $5.79 per share price.On May 4, 2016, Michael Gleeson (SVP, North American Com. Ops.) sold 396 shares at $5.79 per share price.
Shares of GenMark Diagnostics Inc (GNMK) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.14 points or -1.64% at $8.38 with 1,42,704 shares getting traded. Post opening the session at $8.53, the shares hit an intraday low of $8.24 and an intraday high of $8.62 and the price vacillated in this range throughout the day. The company has a market cap of $359 M and the number of outstanding shares has been calculated to be 4,27,88,585 shares. The 52-week high of GenMark Diagnostics Inc is $10.84 and the 52-week low is $4.2.
GenMark Diagnostics Inc. (GenMark) is a molecular diagnostics company. The Company is focused on developing and commercializing its eSensor detection technology. The Company’s electrochemical technology enables detection of multiple distinct biomarkers in a single sample. The Company’s XT-8 system received 510(k) clearance from the United States Food and Drug Administration (FDA) and is designed to support a range of molecular research and diagnostic tests with a workstation and disposable test cartridges. Its XT-8 system supports up to 24 independent test cartridges each of which can be run independently resulting in a workflow for its focused customers which are primarily hospitals and reference laboratories. It has an installed base of approximately 540 XT-8 analyzers or placements with its customers.